对浸润性真菌病病史患者行造血干细胞移植的操作方法
本文综述了在浸润性真菌病(IFD)病史患者中实施造血干细胞移植(HSCT)的围移植期管理。文章评估了影响IFD复发风险的患者、恶性疾病、移植操作、抗真菌治疗及真菌特异性因素,并强调移植后有效监测与抗真菌预防药物选择的重要性。
要点
- IFD病史不再是HSCT绝对禁忌,但需个体化评估复发风险。
- 移植后需有效监测IFD复发并谨慎选择抗真菌预防药物。
- 抗真菌药与钙调神经磷酸酶抑制剂等免疫抑制剂存在相互作用。
核心结论
- 对近期IFD患者行HSCT已日益常见,但需基于多因素个体化决策并加强围移植期管理。
研究设计与样本
- 本文为综述, critically evaluate影响IFD复发风险的因素并提供围HSCT管理指导。
主要发现
- 患者、恶性疾病、移植操作、抗真菌治疗及真菌特异性问题均影响IFD复发风险。
- 有效的移植后IFD复发监测与抗真菌预防药物选择至关重要。
临床怎么用
- 评估IFD病史患者HSCT时需综合考虑患者、疾病、移植、抗真菌治疗及真菌类型等因素。
- 移植后应有效监测IFD复发,并注意抗真菌药与免疫抑制剂的相互作用。
- 特定病例可考虑免疫辅助细胞因子或细胞治疗及手术。
局限性
- 缺乏系统化方案,决策高度个体化。
- 本文为综述,未提供原始研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematopoietic transplantation is the preferred treatment for many patients with hematologic malignancies. Some patients may develop invasive fungal diseases (IFDs) during initial chemotherapy, which need to be considered when assessing patients for transplantation and treatment posttransplantation. Given the associated high risk of relapse and mortality in the post-hematopoietic stem cell transplantation (HSCT) period, IFDs, especially invasive mold diseases, were historically considered a contraindication for HSCT. Over the last 3 decades, advances in antifungal drugs and early diagnosis have improved IFD outcomes, and HSCT in patients with a recent IFD has become increasingly common. However, an organized approach for performing transplantation in patients with a prior IFD is scarce, and decisions are highly individualized. Patient-, malignancy-, transplantation procedure-, antifungal treatment-, and fungus-specific issues affect the risk of IFD relapse. Effective surveillance to detect IFD relapse post-HSCT and careful drug selection for antifungal prophylaxis are of paramount importance. Antifungal drugs have their own toxicities and interact with immunosuppressive drugs such as calcineurin inhibitors. Immune adjunct cytokine or cellular therapy and surgery can be considered in selected cases. In this review, we critically evaluate these factors and provide guidance for the complex decision making involved in the peri-HSCT management of these patients.
引用
- Puerta-Alcalde P, Champlin RE, Kontoyiannis DP, et al. How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. Blood. 2020. PMID: 33301030. doi:10.1182/blood.2020005884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。